Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $9.33 Average Target Price from Analysts

Esperion Therapeutics, Inc. (NASDAQ:ESPR) has earned a consensus recommendation of “Hold” from the five ratings firms that are covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $12.00.

Several equities research analysts recently commented on ESPR shares. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a report on Tuesday, May 21st. StockNews.com downgraded Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 17th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 target price on shares of Esperion Therapeutics in a research note on Tuesday, May 7th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ESPR. Spire Wealth Management grew its holdings in shares of Esperion Therapeutics by 69.2% in the 4th quarter. Spire Wealth Management now owns 17,767 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 7,267 shares during the last quarter. Private Portfolio Partners LLC acquired a new stake in Esperion Therapeutics during the 4th quarter worth about $30,000. Herbst Group LLC purchased a new stake in Esperion Therapeutics during the first quarter valued at about $28,000. Summit Financial LLC boosted its holdings in shares of Esperion Therapeutics by 66.8% in the first quarter. Summit Financial LLC now owns 25,864 shares of the biopharmaceutical company’s stock worth $69,000 after buying an additional 10,355 shares during the period. Finally, PSI Advisors LLC increased its position in shares of Esperion Therapeutics by 161.5% in the fourth quarter. PSI Advisors LLC now owns 17,000 shares of the biopharmaceutical company’s stock worth $51,000 after acquiring an additional 10,500 shares in the last quarter. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Stock Performance

Shares of ESPR opened at $2.99 on Friday. Esperion Therapeutics has a one year low of $0.70 and a one year high of $3.40. The stock’s fifty day moving average is $2.28 and its 200-day moving average is $2.33. The firm has a market capitalization of $566.49 million, a price-to-earnings ratio of -3.02 and a beta of 1.00.

Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.34 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.42. The company had revenue of $137.74 million for the quarter, compared to analyst estimates of $53.11 million. Analysts forecast that Esperion Therapeutics will post -0.05 EPS for the current fiscal year.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.